- In May 2023, Boehringer Ingelheim announced the initiation of clinical development for its first-in-class IL-11 inhibitor antibody, BI 765423. The Phase 1 study (NCT05658107) aims to assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. Pre-clinical studies have shown that this anti-IL-11 medication has the potential to inhibit and even reverse fibrosis in various fibrotic diseases
- In May 2023, Cumberland Pharmaceuticals Inc. disclosed that the FDA had approved an Investigational New Drug Application (IND) for Phase II research involving patients with Idiopathic Pulmonary Fibrosis (IPF), which is the most prevalent form of progressive fibrosing interstitial lung disease
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, and Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, and Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) – Industry Trends and Forecast to 2031
.
The Europe Fibrotic Diseases Treatment Market size was valued at USD 6.18 USD Billion in 2023.
The Europe Fibrotic Diseases Treatment Market is projected to grow at a CAGR of 8.42% during the forecast period of 2024 to 2031.
The market report covers data from the Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and Rest of Europe.
